Afuco™ Anti-Human VEGFC ADCC Therapeutic Antibody (VGX100), ADCC Enhanced
Anti-VEGFC ADCC Enhanced Antibody (VGX100) is an ADCC enhanced antibody produced by our Afuco™ platform. VGX-100 is a human antibody that acts against the human vascular endothelial growth factor (VEGF)-C protein. Treatment for cancers, particularly glioblastoma and metastatic colorectal cancers, are the first target indications for VGX-100. Additionally, VGX-100 is developing for a number of other cancer indications, and as an agent to treat front-of the-eye diseases.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-635CL |
| Pricing | Inquiry |
| Host | Human |
| Target | VEGFC |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Applications | Neut, FuncS |
| Storage | Store at 4°C for up to 3 months. For longer term storage aliquot into small volumes and store at -20°C. |